Epithalon

Epithalon is a tetrapeptide — alanine, glutamic acid, aspartic acid, glycine — developed by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. It is the synthetic successor to Epithalamin, a peptide extract of the pineal gland, and it belongs to the same bioregulator tradition as several other compounds in this catalogue.

The pineal gland is a small structure near the centre of the brain, best known for producing melatonin and for its role in daily and seasonal rhythm. Soviet research from the 1970s onward investigated whether pineal extracts influenced ageing, and that programme produced first the extract and then this defined four-residue peptide intended to reproduce its activity.

The claim that made Epithalon widely discussed is telomerase activation — the idea that it prompts cells to maintain the protective caps on their chromosomes. That is a specific, testable and consequential claim, and it deserves to be examined carefully rather than repeated.

• Telomere maintenance: Chromosome ends shorten each time a cell divides, and that shortening is one of the clocks limiting how many divisions a cell has. A compound proposed to affect it is addressing a well-defined mechanism.

• Short peptides and gene expression: The bioregulator proposal is that very short peptides interact with DNA and influence which genes are read. This compound is one of the most studied test cases for that idea.

• From extract to defined peptide: It represents the step from a tissue extract to a synthetic molecule with a stated sequence, which is the transition that makes a preparation reproducible and properly testable.

• Pineal regulation: The gland's role in daily and seasonal rhythm connects this compound to circadian research, which is a separate strand from the telomere work and less often mentioned.

Chromosomes end in a repeated DNA sequence called a telomere, which functions as a protective cap. Because of how DNA copying works, a little is lost at each division, and when telomeres become short enough the cell stops dividing permanently. This is one of the better-understood limits on the lifespan of a cell, and it is why telomeres appear in almost every discussion of ageing.

The enzyme telomerase can rebuild those caps. It is active in embryonic cells and in some stem cells, largely switched off in ordinary adult tissue — and reactivated in most cancers, which is the reason the off switch exists. Telomerase is not a simple good thing whose absence is an oversight; it is a capability that is deliberately withheld.

The claim about Epithalon is that it prompts telomerase activity in cells where it is normally silent. The proposed route is the general bioregulator mechanism: the peptide is short enough to interact with DNA directly and may influence whether particular genes, including the one encoding telomerase, are read. Both steps in that chain are proposals with partial support rather than established findings, and the second in particular is inferred more than it is demonstrated.

The telomerase work rests principally on cell-culture studies published in the early 2000s by the group that developed the compound, alongside long-term animal studies from the same tradition. It is a substantial body of work from a research programme that ran for decades, with limited independent replication outside it — which is what makes the claim worth testing rather than settled.

The wider bioregulator literature has the same shape: extensive, largely Russian-language, and largely from one lineage of researchers. It holds no medicines approval and is supplied for laboratory research only. Epithalon is the most studied compound in that tradition, and the telomere question it raises is specific enough to be tested directly — which is why it remains one of the most requested peptides in ageing research.

Pinealon is the closest relative — a three-residue bioregulator from the same institute, studied in the nervous system rather than in relation to telomeres, and resting on the same proposed mechanism.

NAD+ and MOTS-c approach cellular ageing through metabolism instead, and the contrast is instructive: one tradition proposes gene regulation by short peptides, the other measures defined biochemical pathways. FOXO4-DRI is a third position again — removing cells that have stopped dividing rather than changing what any cell does.